SJ733 + Cobicistat

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Malaria

Conditions

Malaria

Trial Timeline

Mar 1, 2016 → Mar 9, 2018

NCT ID

NCT02661373

About SJ733 + Cobicistat

SJ733 + Cobicistat is a phase 1 stage product being developed by Eisai for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT02661373. Target conditions include Malaria.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02661373	Phase 1	Completed	Mar 1, 2016	Mar 9, 2018	Malaria

Competing Products

20 competing products in Malaria

See all competitors

Product	Company	Stage	Hype Score
SAR97276A	Sanofi	Phase 2	51
(+)-SJ000557733 (SJ733)	Eisai	Phase 2	52
E1018 + Placebo	Eisai	Phase 1	33
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	33
ZY19489 Capsule + Placebo Capsule	Zydus Lifesciences	Phase 1	33
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mg	Merck	Phase 2	52
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanil	Merck	Phase 1	33
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mg	Merck	Phase 2	52
KLU156 + Coartem	Novartis	Phase 3	77
KAF156	Novartis	Phase 2	52
KAE609 + IV Artesunate + Coartem	Novartis	Phase 2	52
KAE609	Novartis	Phase 2	52
artemether:lumefantrine (2.5 mg:30 mg)	Novartis	Phase 2/3	65
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	65
INE963	Novartis	Phase 2	52
Ganaplacide + Itraconazole	Novartis	Phase 1	33
KAE609 + Piperaquine Phosphate	Novartis	Phase 1	33
Artemether-lumefantrine	Novartis	Phase 3	77
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	52
KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation	Novartis	Phase 2	52

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved